By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Tobira Therapeutics Inc. 

214 Carnegie Center
Suite 306
Princeton  New Jersey  08540  U.S.A.
Phone: 609-897-1102 Fax: n/a


SEARCH JOBS








Company News
Tobira Therapeutics Inc. Highlights Data Presentations At The American Association for Study of Liver Diseases Annual Meeting Supporting Its Phase 2b Program Of Cenicriviroc For Nonalcoholic Steatohepatitis 11/10/2014 9:11:09 AM
Tobira Therapeutics Inc. Doses First Patient In CENTAUR, A Phase 2b Study Of Cenicriviroc In Patients With Non-Alcoholic Steatohepatitis 10/13/2014 7:39:29 AM
Tobira Therapeutics Inc.' Cenicriviroc Shows Improvement In Liver Fibrosis Scores In Phase 2b Study To Be Presented At AASLD 10/1/2014 8:53:13 AM
Bay Area Biotech Firm Tobira Therapeutics Inc. Tables $74 Million IPO 8/7/2014 3:15:50 PM
South San Francisco's Tobira Therapeutics Inc. Wraps Up $15 Million Loan Agreement 7/1/2014 7:05:52 AM
Tobira Therapeutics Inc. Adds To Its Board Of Directors 6/23/2014 8:15:16 AM
Tobira Therapeutics Inc. Appoints Chairman Laurent Fischer, MD, Chief Executive Officer And Christopher Peetz Chief Financial Officer 3/26/2014 1:20:31 PM
Tobira Therapeutics Inc. Presents Data Supporting Anti-Fibrotic Activity of Cenicriviroc in Liver Disease Models at The Liver Meeting 2013 11/4/2013 6:43:07 AM
Tobira Therapeutics Inc. Presents Positive 48-Week Data From Phase 2b Trial of Cenicriviroc in Treatment-Naïve HIV Infection at the 14th European AIDS Conference 10/17/2013 7:08:04 AM
Tobira Therapeutics Inc. Announces Publication of Cenicriviroc Formulation Improvement Providing Platform for Single Tablet and Fixed-Dose Combinations 10/4/2013 9:54:09 AM
1234
//-->